RecruitingNot Applicable

Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa

France600 participantsStarted 2025-03-11

Plain-language summary

The primary objective of the ADDICT study is to assess and compare the clinical efficacy of available options for antimicrobial therapy (new beta-lactam/beta-lactamase inhibitor combination, cefiderocol or older agents such as aminoglycosides and colistin) in unselected patients with infection due to difficult-to-treat P. aeruginosa.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All patients aged 18 or over and requiring intravenous definite antimicrobial therapy for a DTR P. aeruginosa infection Exclusion Criteria: * Cystic fibrosis * P. aeruginosa DTR colonization or P. aeruginosa DTR infection not requiring definitive intravenous antibiotic therapy * Protected person (under guardianship or curatorship) * Persons under court protection * Persons deprived of liberty * Opposition expressed for participation in the study

What they're measuring

Clinical cure rate

Timeframe: Test of cure visit

Clinical cure

Timeframe: Day 7±2 after the completion of definite therapy

Trial details

NCT IDNCT06738771

SponsorCentre Hospitalier Régional d'Orléans

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-01

Contact for this trial

FRANCOIS BARBIER, Professor

+33238229939 francois.barbier@chu-orleans.fr

View on ClinicalTrials.gov More Pseudomonas Infections trials